Connor Iapoce

Most patients with AMD and glaucoma demonstrated standard postural control and a lower fall risk than patients with vestibular disorders.

When the current recommended diagnostic algorithm was used in clinical practice, antibody testing was required in half of patients with suspected HIT.

A systematic review and meta-analysis of HSCT in children with sickle cell disease demonstrated pooled survival rates exceeding 90%.

Despite the availability of anti-VEGF therapies, there is still a notable disease burden in older adults with vision-threatening retinal diseases.

Oral iron supplements did not significantly differ in increasing hemoglobin and ferritin levels, but the every-other-day oral iron proved more effective than daily use.

Adults with strabismus in a diverse nationwide cohort were approximately 2 to 3 times more likely to experience mental health conditions.

Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.

Alberto Foà, MD, PhD, discusses a PARAGON-HF analysis from ACC.24 examining treatment-related hypotension in people with HFmrEF/HFpEF.

Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.

National data show older Americans with vision impairment were less likely to have access to digital technology than counterparts without impairments.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our March 2024 ophthalmology month in review features a recap of the latest news from the ophthalmic pipeline.

Prices of nearly all insulins, SGLT2 inhibitors, and GLP1As could be reduced if robust generic or biosimilar manufacture were enabled.

Peter A. Campochiaro, MD, discusses the safety and tolerability of RGX-314 gene therapy in treating wet AMD and how these results inform pivotal clinical trials.

Our March 2024 month-in-review in hematology features updates to the anemia pipeline, the latest research in sickle cell disease, and the role of SGLT2 inhibition on hematologic outcomes.

The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.

Positive phase 2 results from NEPTUNE represent the best treatment failure rates observed among active studies in non-infectious uveitis.

In a systematic review and meta-analysis of available data, lotilaner ophthalmic solutions outperformed placebo, with few side effects, in treating Demodex blepharitis.

Topline results from AURORA indicate that while bitopertin significantly reduced PPIX levels, improvements in light tolerance were not statistically significant.

Iron-deficient patients on an SGLT2 inhibitor at baseline experienced greater increases in hemoglobin levels with ferric derisomaltose compared with those not taking one.

A systematic review highlights the available evidence on the use of intravenous fluid in sickle cell vaso-occlusive crises and reported adverse outcomes.

An analysis of the CLEAR Outcomes trial suggests bempedoic acid was well-tolerated in Hispanic/Latinx and non-Hispanic/Latinx individuals with statin intolerance.

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.

A new analysis summarized evidence on the effects of allogeneic HSCT on SCD-related organ dysfunction in pediatric and adult patients with SCD.

A posthoc analysis of two phase 3 trials identified multiple independent factors associated with better response to vadadustat in patients with anemia.

Adults with higher triglyceride levels exhibit a higher prevalence of chronic conditions and multi-organ disease.

A study in China identified a negative and non-linear relationship between hemoglobin levels and a renal composite end point in patients with DKD.

Deepak Sambhara, MD, discusses how clinical practice has responded to the introduction of aflibercept 8 mg and the significance of extended treatment intervals for patients with retinal diseases.

Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.

A significant association between Lp(a) and adverse cardiovascular outcomes was altered by renal function in patients undergoing percutaneous coronary intervention.